Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
– 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI)…
Artmarket.com: H1 2026 Financial Report–One-of-a-Kind AI Systems Intuitive Artmarket® and Blind Spot Will Drive the Next Phase of Growth for "AI-First" Artprice in 2026-2030
PARIS, Sept. 29, 2026 /PRNewswire/ — Artmarket.com announces that its 120 pages…